In order to request this CME/CE activity for your center, please contact Samantha Zelasko at SZelasko@gotoper.com

Friday, December 15, 2023 | 3:00 - 4:00 PM ET

Register Here

Tuesday, December 19, 2023 | 12:00 - 1:00 PM ET

Register Here

Thursday, December 21, 2023 | 12:00 - 1:00 PM ET

Register Here

Best Practice™ is a nationwide series of regional live grand rounds/visiting speaker programs, held in locations across the US deemed to have the highest educational need. This activity will serve to update hemophilia treatment centers (HTCs) with a curriculum focused on evidence-based strategies that assure optimized gene therapy outcomes and clinical decision-making in the care of patients with hemophilia B.

Despite recent improvements in treatment options, hemophilia B continues to have a significant negative impact on patients’ functionality and health-related quality of life. Gene therapy for hemophilia B has the potential to reduce the treatment burden for patients and their care providers by eliminating the need for regular prophylaxis. Certain challenges associated with gene therapy still need to be addressed in order to ensure widespread therapeutic use, but it offers a promising option for this patient population. Hemophilia treatment centers (HTCs) have already been established to ensure multidisciplinary care for patients, incorporating clinical specialties, emergency departments and appropriate laboratory facilities. Overall, gene therapy for hemophilia presents a challenge to the existing structure of HTCs and requires enhanced collaboration and information sharing in order to maximize benefits and minimize risks. A “hub and spoke” model has been proposed to ensure time and expertise for patient counselling, informed consent, and to clearly demarcate responsibility for different aspects of the procedure. This educational activity will address the evolving treatment paradigm for hemophilia B including the role of gene therapy and how this may change the way in which hemophilia care is delivered.

• Hear an expert discuss the basis for gene therapy in hemophilia B
• Learn about the risks and benefits of gene therapy
• Understand which patients are candidates for gene therapy
• Analyze the risks of gene therapy

This CME program is supported by an educational grant from CSL Behring LLC.

This educational activity is directed toward hematologists, specialty NP/PAs, pharmacists, and nurses who manage patients with hemophilia B.

Upon completion of this activity, participants will be able to:

• Identify the role of gene therapy in the treatment paradigm for hemophilia B
• Describe models for implementation of gene therapy for hemophilia B into clinical practice
• Discuss the role of the multidisciplinary team in the management of patients receiving gene therapy for hemophilia B

Steven W. Pipe, MD

Laurence A. Boxer Research Professor of Pediatrics and Communicable Diseases
Professor of Pathology
Director, Pediatric Hemophilia and Coagulation Disorders Program
Medical Director, Special Coagulation Laboratory
University of Michigan
Ann Arbor, MI

Physicians’ Education Resource (PER) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This activity will be made available for 1.25 AMA PRA Category 1.0 Credits.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 1.25 Contact Hours